News
The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.
The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback